Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00495638 · ClinicalTrials.gov registry record

Pulmonary Hypertension, Hypoxia and Sickle Cell Disease

A clinical trial of Pulmonary Hypertension and Sickle Cell Anemia, sponsored by National Heart, Lung, and Blood Institute (NHLBI).

Completed
Registry status
29
Enrollment target
7
Study locations

NCT00495638 is a study of Pulmonary Hypertension and Sickle Cell Anemia that has completed, run by National Heart, Lung, and Blood Institute (NHLBI). The registered enrollment target is 29 participants, below the 613-participant average among 72 other Pulmonary Hypertension trials with a reported enrollment target (95% lower). The trial reports 7 study locations across 6 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00495638, a study of Pulmonary Hypertension and Sickle Cell Anemia, has completed, sponsored by National Heart, Lung, and Blood Institute (NHLBI).

COMPLETED
Registry status
29 participants
Enrollment target
7
Study locations

Study Summary

The study will look at the risk factors for pulmonary hypertension (high blood pressure in the lungs) in children and adolescents with sickle cell anemia (SCA) and examine the role of hypoxia (oxygen shortage) in the disease. In patients with SCA, red blood cells become sickle-shaped and tend to form clumps that get stuck in blood vessels, blocking blood flow to the limbs and organs. Blocked blood vessels can cause pain, serious infections, and organ damage. Many patients with SCA also develop pulmonary hypertension. Children and adolescents with SCA or Chuvash polycythemia (another blood disorder that carries an increased risk for pulmonary hypertension) may be eligible for this study. Participants undergo the following procedures at the beginning (baseline) and end of the study: * History, physical examination and blood tests . * Echocardiography (ultrasound study of heart function). * Transcranial doppler (brain ultrasound study to measure brain blood flow). * Lung function tests. * 6-minute walk (measure of the distance covered in 6 minutes of walking). In addition, patients are followed by telephone or by clinic visits every 6 months for a review of their medical history and medications. A physical examination is also done at 12 months.

Study Locations (7)

District of Columbia

  • Howard University Hospital - Washington D.C.
  • Childrens National Medical Center - Washington D.C.

Illinois

  • University of Chicago - Chicago

Maryland

  • National Institutes of Health Clinical Center, 9000 Rockville Pike - Bethesda

Michigan

  • University of Michigan - Ann Arbor

Texas

  • Baylor College of Medicine - Houston

Other

  • Republic Cardiac Center in Cheboksary - Chuvashia

Trial Details

FieldValue
Enrollment Target 29 participants
Start Date 2007-06-28
Est. Completion 2014-12-02

What the Registry Record Tells You About NCT00495638

The ClinicalTrials.gov registry entry for NCT00495638 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 29 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 613-participant average among 72 other Pulmonary Hypertension trials with a reported enrollment target (95% lower). The listed sponsor is National Heart, Lung, and Blood Institute (NHLBI), which has 501 total studies on file at ClinicalTrials.gov.

The record links to 4 conditions, with Pulmonary Hypertension appearing as the primary indexed condition, and to 0 interventions.

NCT00495638 reports 7 study locations spanning 6 distinct geographic areas - top geographies include District of Columbia, Illinois, Maryland.

Frequently Asked Questions

What is clinical trial NCT00495638 about?

NCT00495638 is a clinical study titled "Pulmonary Hypertension, Hypoxia and Sickle Cell Disease". The study will look at the risk factors for pulmonary hypertension (high blood pressure in the lungs) in children and adolescents with sickle cell anemia (SCA) and examine the role of hypoxia (oxygen shortage) in the disease. In patients with SCA, red blood cells become sickle-shaped and tend to for...

What is the current status of trial NCT00495638?

This trial is currently completed. The enrollment target is 29 participants. The study started on 2007-06-28. Estimated completion is 2014-12-02.

What conditions does trial NCT00495638 study?

This clinical trial studies the following conditions: Pulmonary Hypertension, Sickle Cell Anemia, Cerebrovascular Disease, Chuvash Polycythemia.

Who is sponsoring clinical trial NCT00495638?

This trial is sponsored by National Heart, Lung, and Blood Institute (NHLBI), which has 501 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00495638 being conducted?

This trial has 7 study locations across District of Columbia, Illinois, Maryland, Michigan, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Pulmonary Hypertension

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.